CASE REPORT
Accepted on 15 Oct 2025
Case report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma
doi 10.3389/fimmu.2025.1697566
- 191 views
- Frontiers in Oncology
- Hematologic Malignancies
- Research Topics
- Chimeric Antigen Receptor T Cell Therapies and Bispecific Antibodies in Hematologic Malignancies
Chimeric Antigen Receptor T Cell Therapies and Bispecific Antibodies in Hematologic Malignancies
567
Total downloads
6,240
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
ORIGINAL RESEARCH
Accepted on 08 Oct 2025
Post-Progression Outcomes Following BCMA-Directed CAR T-Cell Therapy in Myeloma: Impact of Extramedullary and Paramedullary Disease
doi 10.3389/fonc.2025.1663814
- 245 views
SYSTEMATIC REVIEW
Published on 29 Sep 2025
CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed/refractory follicular lymphoma: a literature review and meta-analysis
doi 10.3389/fimmu.2025.1611984
- 2,619 views
CASE REPORT
Published on 18 Sep 2025
Case Report: Safety and efficacy assessment of teclistamab in relapsed/refractory amyloidosis: a case study
doi 10.3389/fonc.2025.1664171
- 1,245 views
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
You will be redirected to our submission process.